drugset / Trial / NCT02509845

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

NCT02509845 ↗

Phase 2 Completed 64 enrolled Armata Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of the clinical study is to evaluate the safety and bacterial impact of study drug (C16G2) administered in multiple oral gel doses to adolescent and adult dental subjects.

Timeline

Start
2015-07
Primary completion
2016-02
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject C16G2 Peptide 2 ml Oral
Subject C16G2 Peptide 4 ml Oral

Indications